Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7895769rdf:typepubmed:Citationlld:pubmed
pubmed-article:7895769lifeskim:mentionsumls-concept:C0007634lld:lifeskim
pubmed-article:7895769lifeskim:mentionsumls-concept:C0030274lld:lifeskim
pubmed-article:7895769lifeskim:mentionsumls-concept:C0021467lld:lifeskim
pubmed-article:7895769lifeskim:mentionsumls-concept:C0439232lld:lifeskim
pubmed-article:7895769lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:7895769lifeskim:mentionsumls-concept:C0439799lld:lifeskim
pubmed-article:7895769lifeskim:mentionsumls-concept:C0205132lld:lifeskim
pubmed-article:7895769lifeskim:mentionsumls-concept:C1524031lld:lifeskim
pubmed-article:7895769lifeskim:mentionsumls-concept:C0254772lld:lifeskim
pubmed-article:7895769lifeskim:mentionsumls-concept:C0205198lld:lifeskim
pubmed-article:7895769pubmed:issue3lld:pubmed
pubmed-article:7895769pubmed:dateCreated1995-4-24lld:pubmed
pubmed-article:7895769pubmed:abstractTextWe studied the mechanism of action of KAD-1229, a non-sulfonylurea compound shown to stimulate insulin secretion, in a glucose responsive insulinoma cell line, MIN 6 cells. In microsomal fraction of MIN 6 cells, KAD-1229 displaced binding of [3H]glibenclamide in a concentration-dependent manner. The dissociation constant and the maximum binding capacity were 0.61 nM and 8.70 pmol/mg.protein, respectively. In inside out configuration of patch-clamp technique, KAD-1229 attenuated the opening of ATP-sensitive K+ channels. The effect of KAD-1229 was detected at 10(-8) M, and 10(-5) M KAD-1229 almost completely blocked the activity of ATP-sensitive K+ channel. When membrane potential was monitored by a perforated mode of patch clamp, KAD-1229 induced depolarization of plasma membrane, which was followed by a burst of action potentials. These action potentials were blocked by cobalt. In a fura-2-loaded single MIN 6 cell, KAD evoked an elevation of intracellular free Ca2+ concentration, [Ca2+]i. The KAD-1229-mediated elevation of [Ca2+]i was attenuated by either removal of extracellular Ca2+ or an addition of nifedipine. Finally, KAD-1229 augmented insulin secretion in MIN 6 cells in a concentration-dependent manner. KAD-1229 also enhanced the effect of glucose and nifedipine inhibited the action of KAD-1229 on insulin secretion. These results indicate that KAD-1229 stimulates insulin secretion by stimulating Ca2+ influx and that, despite the lack of sulfonylurea structure, KAD-1229 binds to sulfonylurea receptors and inhibits the activity of ATP-sensitive K+ channel in MIN 6 cells.lld:pubmed
pubmed-article:7895769pubmed:languageenglld:pubmed
pubmed-article:7895769pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7895769pubmed:citationSubsetIMlld:pubmed
pubmed-article:7895769pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7895769pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7895769pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7895769pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7895769pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7895769pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7895769pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7895769pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7895769pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7895769pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7895769pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7895769pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7895769pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7895769pubmed:statusMEDLINElld:pubmed
pubmed-article:7895769pubmed:monthNovlld:pubmed
pubmed-article:7895769pubmed:issn0014-2999lld:pubmed
pubmed-article:7895769pubmed:authorpubmed-author:ShibataHHlld:pubmed
pubmed-article:7895769pubmed:authorpubmed-author:MogamiHHlld:pubmed
pubmed-article:7895769pubmed:authorpubmed-author:KojimaIIlld:pubmed
pubmed-article:7895769pubmed:authorpubmed-author:MiyazakiJJlld:pubmed
pubmed-article:7895769pubmed:authorpubmed-author:OhnotaHHlld:pubmed
pubmed-article:7895769pubmed:authorpubmed-author:SatoiJJlld:pubmed
pubmed-article:7895769pubmed:authorpubmed-author:NobusawaRRlld:pubmed
pubmed-article:7895769pubmed:issnTypePrintlld:pubmed
pubmed-article:7895769pubmed:day15lld:pubmed
pubmed-article:7895769pubmed:volume269lld:pubmed
pubmed-article:7895769pubmed:ownerNLMlld:pubmed
pubmed-article:7895769pubmed:authorsCompleteYlld:pubmed
pubmed-article:7895769pubmed:pagination293-8lld:pubmed
pubmed-article:7895769pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:7895769pubmed:meshHeadingpubmed-meshheading:7895769-...lld:pubmed
pubmed-article:7895769pubmed:meshHeadingpubmed-meshheading:7895769-...lld:pubmed
pubmed-article:7895769pubmed:meshHeadingpubmed-meshheading:7895769-...lld:pubmed
pubmed-article:7895769pubmed:meshHeadingpubmed-meshheading:7895769-...lld:pubmed
pubmed-article:7895769pubmed:meshHeadingpubmed-meshheading:7895769-...lld:pubmed
pubmed-article:7895769pubmed:meshHeadingpubmed-meshheading:7895769-...lld:pubmed
pubmed-article:7895769pubmed:meshHeadingpubmed-meshheading:7895769-...lld:pubmed
pubmed-article:7895769pubmed:meshHeadingpubmed-meshheading:7895769-...lld:pubmed
pubmed-article:7895769pubmed:meshHeadingpubmed-meshheading:7895769-...lld:pubmed
pubmed-article:7895769pubmed:meshHeadingpubmed-meshheading:7895769-...lld:pubmed
pubmed-article:7895769pubmed:meshHeadingpubmed-meshheading:7895769-...lld:pubmed
pubmed-article:7895769pubmed:meshHeadingpubmed-meshheading:7895769-...lld:pubmed
pubmed-article:7895769pubmed:meshHeadingpubmed-meshheading:7895769-...lld:pubmed
pubmed-article:7895769pubmed:meshHeadingpubmed-meshheading:7895769-...lld:pubmed
pubmed-article:7895769pubmed:meshHeadingpubmed-meshheading:7895769-...lld:pubmed
pubmed-article:7895769pubmed:meshHeadingpubmed-meshheading:7895769-...lld:pubmed
pubmed-article:7895769pubmed:meshHeadingpubmed-meshheading:7895769-...lld:pubmed
pubmed-article:7895769pubmed:meshHeadingpubmed-meshheading:7895769-...lld:pubmed
pubmed-article:7895769pubmed:meshHeadingpubmed-meshheading:7895769-...lld:pubmed
pubmed-article:7895769pubmed:meshHeadingpubmed-meshheading:7895769-...lld:pubmed
pubmed-article:7895769pubmed:meshHeadingpubmed-meshheading:7895769-...lld:pubmed
pubmed-article:7895769pubmed:meshHeadingpubmed-meshheading:7895769-...lld:pubmed
pubmed-article:7895769pubmed:meshHeadingpubmed-meshheading:7895769-...lld:pubmed
pubmed-article:7895769pubmed:meshHeadingpubmed-meshheading:7895769-...lld:pubmed
pubmed-article:7895769pubmed:year1994lld:pubmed
pubmed-article:7895769pubmed:articleTitleInhibition of ATP-sensitive K+ channel by a non-sulfonylurea compound KAD-1229 in a pancreatic beta-cell line, MIN 6 cell.lld:pubmed
pubmed-article:7895769pubmed:affiliationCell Biology Research Unit, Institute of Endocrinology, Gunma University, Maebashi, Japan.lld:pubmed
pubmed-article:7895769pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7895769lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7895769lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7895769lld:pubmed